Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug
Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug
Categories: gothenburg life science
-
-
Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel
Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel
-
Advancing siRNA Drug Discovery and Development with AI
Advancing siRNA Drug Discovery and Development with AI
-
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
-
First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim
First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim
-
Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia
Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia.
-
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics
-
Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
-
Ribo presented the first clinical data from our completed Ph1 study of the world´s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.
Ribo presented the first clinical data from our completed Ph1 study of the world´s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.
-
Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the worlds first siRNA drug targeting Factor XI: RBD4059
Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the worlds first siRNA drug targeting Factor XI: RBD4059
-
Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe
Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe
-
Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)
Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)
-
Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA
Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. The trial will evaluate the efficacy and safety of its novel siRNA asset RBD1016, for the treatment of the rare disease of chronic hepatitis D infection.
-
Ribocure supports RARE DISEASE DAY on February 29th
Ribocure supports RARE DISEASE DAY on February 29th
-
Ribo samarbetar med Boehringer Ingelheim för att utveckla nya behandlingar mot leversjukdomar
Ribo samarbetar med Boehringer Ingelheim för att utveckla nya behandlingar mot leversjukdomar
-
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
-
Viktig milstolpe nådd när Ribocure Clinic tar in sina första patienter
Viktig milstolpe nådd när Ribocure Clinic tar in sina första patienter
